doi: 10.1161/hc0302.103593
(Circulation. 2002;105:286.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
Neutral Endopeptidase Is Activated in Cardiomyocytes in Human Aortic Valve Stenosis and Heart Failure
From the Klinik für Herz-, Gefäß- und Thoraxchirurgie, DHZB (R.P., H.R.Z., R.H., V.R.-Z.), Berlin, Germany; Franz-Volhard-Klinik/Charite (J.F.), Berlin, Germany; Medical University Pharmacology and Toxicology (A.D.), Luebeck, Germany; Institut für Zellbiologie, ETH (E.E.), Zurich, Switzerland; and Cardiovascular Center (J.B.), Aalst, Belgium.
Correspondence to Vera Regitz-Zagrosek, DHZB, Augustenburger Platz 1, 13353 Berlin, Germany. E-mail zagrosek{at}dhzb.de
Background— The regulation of the cardiac neutral endopeptidase (EC 24.10, NEP) that degrades bradykinin and natriuretic peptides has been investigated in human cardiac hypertrophy and heart failure.
Methods and Results— NEP mRNA was quantitated by real-time polymerase chain reaction (PCR) in left ventricular biopsies from patients with aortic valve stenosis (AS, n=19) and heart failure due to dilated cardiomyopathy (DCM, n=14), and control subjects with normal systolic function (CON, n=14). Left ventricular NEP mRNA content was increased 3-fold in AS (P<0.005) and 4.1-fold in DCM (P<0.002). The increase in NEP mRNA was related to the increase in end diastolic pressure in AS and DCM. In a second series, myocardial NEP enzymatic activity was determined. It increased 3.6-fold in AS (P<0.02) and 4-fold in DCM (P<0.002). NEP was localized in the myocardium by immunofluorescence microscopy and in situ PCR to myocytes and nonmyocyte areas and cells.
Conclusions— Elevated cardiac NEP activity in pressure loaded and failing human hearts may increase the local degradation of bradykinin and natriuretic peptides.
Key Words: hypertrophy • cardiomyopathy • heart failure • metalloproteinases
This article has been cited by other articles:
 |
|
 |
|
  F Bauer, F Mghaieth, N Dervaux, E Donal, G Derumeaux, A Cribier, and J-P Bessou Preoperative tissue Doppler imaging differentiates beneficial from detrimental left ventricular hypertrophy in patients with surgical aortic stenosis. A postoperative morbidity study Heart, November 1, 2008; 94(11): 1440 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Helske, M. Laine, M. Kupari, J. Lommi, H. Turto, L. Nurmi, I. Tikkanen, K. Werkkala, K. A. Lindstedt, and P. T. Kovanen Increased expression of profibrotic neutral endopeptidase and bradykinin type 1 receptors in stenotic aortic valves Eur. Heart J., August 1, 2007; 28(15): 1894 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maloyan, J. Gulick, C. G. Glabe, R. Kayed, and J. Robbins Exercise reverses preamyloid oligomer and prolongs survival in {alpha}B-crystallin-based desmin-related cardiomyopathy PNAS, April 3, 2007; 104(14): 5995 - 6000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Fielitz, S. Philipp, L. R. Herda, E. Schuch, B. Pilz, C. Schubert, V. Gunzler, R. Willenbrock, and V. Regitz-Zagrosek Inhibition of prolyl 4-hydroxylase prevents left ventricular remodelling in rats with thoracic aortic banding Eur J Heart Fail, April 1, 2007; 9(4): 336 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Singh, R. E. Kuc, J. J. Maguire, M. Fidock, and A. P. Davenport Novel Snake Venom Ligand Dendroaspis Natriuretic Peptide Is Selective for Natriuretic Peptide Receptor-A in Human Heart: Downregulation of Natriuretic Peptide Receptor-A in Heart Failure Circ. Res., July 21, 2006; 99(2): 183 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Philipp, J. S. Jurgensen, J. Fielitz, W. M. Bernhardt, A. Weidemann, A. Schiche, B. Pilz, R. Dietz, V. Regitz-Zagrosek, K.-U. Eckardt, et al. Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats Eur J Heart Fail, June 1, 2006; 8(4): 347 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schupp, U. Kintscher, J. Fielitz, J. Thomas, R. Pregla, R. Hetzer, T. Unger, and V. Regitz-Zagrosek Cardiac PPAR{alpha} expression in patients with dilated cardiomyopathy Eur J Heart Fail, May 1, 2006; 8(3): 290 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Martinka, J. Fielitz, A. Patzak, V. Regitz-Zagrosek, P. B. Persson, and H. M. Stauss Mechanisms of blood pressure variability-induced cardiac hypertrophy and dysfunction in mice with impaired baroreflex Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2005; 288(3): R767 - R776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L.M. Cruden, K. A.A. Fox, C. A. Ludlam, N. R. Johnston, and D. E. Newby Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin-Converting Enzyme Inhibition Hypertension, December 1, 2004; 44(6): 913 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Rosenkranz, S. G. Hood, R. L. Woods, G. J. Dusting, and R. H. Ritchie B-Type Natriuretic Peptide Prevents Acute Hypertrophic Responses in the Diabetic Rat Heart: Importance of Cyclic GMP Diabetes, September 1, 2003; 52(9): 2389 - 2395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Chen, J. G. Lainchbury, and J. C. Burnett Jr Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1186 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Elkayam, M. W. Akhter, P. Tummala, S. Khan, and H. Singh Nesiritide: A New Drug for the Treatment of Decompensated Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2002; 7(3): 181 - 194. [Abstract] [PDF]
|
|